A Salvat company
What drives Pharmaloop
delivery and manufacturing
More than 60 years of innovation
Founded Laboratorios Salvat
Tomas Miarnau and Dr. Antonio Salvat founded the Company in Barcelona in 1955. Today Salvat is still a family business, led by the descendants of Jose Maria Peris Miarnau, lawyer and nephew of one of the founders, and Elvira Maria Teresa Musso Borras.
Launch of Salvacolina®
Salvacolina® became our first big brand. Dr. Montserrat invented the product, indicated for the symptomatic treatment of unspecific acute diarrhea.
Establishment of the Research, Synthesis and Development Department
This expansion allowed Salvat to achieve full vertical integration at a time when basic research and organic chemistry were the differentiating factors for growing pharmaceutical companies.
Cristalmina® (topical clorhexidine gluconate)
Cristalmina® is an OTC topical antiseptic, leader in the Spanish market and the flagship brand of Salvat.
Cetraxal® Otic (worldwide innovation ciprofloxacin otic solution)
With the launch of Cetraxal® Otic in the 90s we expanded to dominate the Spanish topical antibiotic market, and became a referent in the treatment of ear infections.
Monolitum® (Lansoprazole – own pellets technology)
Around our proprietary Orally Dispersible Tablet technology, we developed Monolitum®. Two decades later, it remains as the go-to product for acute treatment of duodenal ulcers, gastric ulcers and oesophagitis due to gastro-oesophageal reflux.
New R&D Center
With the new millennium we launched a new Research and Development center, primarily focused on pharmaceutical technologies.
Cetraxal® Plus (unique combination ciprofloxacin + fluocinolone otic solution)
Cetraxal® Plus became the first combination of this kind for the treatment of ear infections. With the launch of this product we were solidified as leaders in the otology field.
Ebernet® (New chemical entity: Eberconazole)
Our first new chemical entity to reach the market, Ebernet® is sold in 3 continents and we continue to expand its use in alternative indications.
SALVAT USA Inc. is founded. New offices in Miami, FL
With the opening of this wholly owned subsidiary we made a commitment to continue to grow and innovate in the US market.
Blow-Fill-Seal technology is introduced at our production facility
A decade ago we identified Blow-Fill-Seal (BFS) as the technology of the future for aseptic and preservative manufacturing. BFS would soon become the basis of our innovation and would allow us to develop leading products for international markets.
Malacur® launched in Africa
Malacur® has grown to be one of the go-to brands for the treatment of malaria in Africa. The product allowed us to expand our presence through various African territories.
FDA approval and US launch of Cetraxal® Otic in single use vials
A new star was born in 2009 with the launch of Cetraxal® Otic in the US. In combination with our Blow-Fill-Seal technology, we led the full development of the product to become the first Spanish pharmaceutical company with a marketed Rx product in the US.
Otovel® (ciprofloxacin + fluocinolone) partnerships and launches in multiple regions, including the USA
Shortly following the launch of our first product in the US, we launched the second, Otovel®. Its current and future indications have the potential to become the leading brand for the topical treatment of ear infections in the US.
New Blow-Fill-Seal manufacturing line in the USA
With our growing presence in the US, we identified the opportunity to own our first FDA-approved manufacturing facility. This expanded facility in the US will increase efficiency and will assist us with local innovation while offering contract manufacturing services to third parties.
Pharmaloop: Acquisition of new manufacturing site in Madrid
With the acquisition of Pharmaloop in Madrid we expanded our production capacity, and we established the foundation for the growth of our contract development and contract manufacturing businesses.